Tempest enters China CAR-T collaboration with Senlang, targeting Q4 2026 trial start

Filed July 22, 2026 · Period ending July 17, 2026 · ~1 min read

Key Changes

• high

  Tempest partnered with Senlang Biotechnology to develop TPST-4003, a CD7-targeted in vivo CAR-T candidate, beginning with a ~10-patient trial in myasthenia gravis or multiple sclerosis in China. First patient dosing expected Q4 2026, with initial safety and pharmacodynamic data as early as H1 2027.

  Item 1.01 verify on EDGAR →
• medium

  Tempest will pay Senlang $1.5M-$2.0M per product for development activities, with payments tied to milestones and a $2.0M cap per product unless additional amounts are approved in writing. Tempest retains worldwide, royalty-free rights to all trial data.

  Item 1.01 verify on EDGAR →
• medium

  Senlang received an exclusive option to negotiate China development and commercialization rights for TPST-4003 after completing the agreed trial data package. Tempest maintains global rights outside any future China license.

  Item 1.01 verify on EDGAR →